(BW) (CA-ELSEVIER-MDL) (RUK) (ENL) (REL.L) (REN.AS) 把研发数据及工作流进行整合的新方法在制药领域获得了发展动力

更多向MDL(R) Isentris(R)移植的公司提高了生产力，降低了成本，并为科学家提供了更大的控制能力

美国商业资讯2007年2月21日加利福尼亚州圣雷蒙消息——

爱思唯尔MDL公司（Elsevier MDL）宣布，超过75家制药、生物技术及化学公司已经获得这项新的开放型技术MDL(R) Isentris(R)系统的许可，来应对共同的研发挑战。转用新一代Isentris系统的领先研究公司包括一半以上的爱思唯尔MDL公司30家顶级客户。　

爱思唯尔MDL公司在其举办的一次论坛上作出了上述宣布。此次论坛是针对全球研究及IT人员为解决减少研发时间、削减成本及提高生产力所面临的策略及新的信息技术问题而举办的。

爱思唯尔MDL公司总裁兼首席执行官Lars Barfod说：“十多年来，几乎所有的主要制药公司在它们的实验室里都依赖现行标准MDL(R) ISIS(R)技术。现在，许多公司看到了通过向Isentris移植，在它们的运营中实现更佳业绩的可能性。最新推出的Isentris 2.0从功能性、性能及降低拥有成本方面来说均大大超越了ISIS及竞争的系统。”

凭借Isentris，企业可以使科学家在正常的工作流中更加方便地获取相关数据，促进工具与依数据进行决策所必须能力的协调。Isentris包括针对快速构建拥有强大科学能力的定制化、易用研究环境的.NET控制。

Elsevier MDL公司高级副总裁兼首席科学官Trevor Heritage博士说：“日益增多的向Isentris移植，反应了针对科学家的一个新时代Informatics 2.0的来临。研究人员可以不依赖于IT支持，控制提出和获取他们需要立即回答问题及测试设想数据的特定观点。”

该管理论坛引述的一个经典案例中，一家已经从ISIS移植到Isentris的欧洲制药公司称赞该系统所拥有的大幅改进的整合性及易用性，以及科学家在生物化验数据、化学以及其他实验和计算数据一出来后并获得这些数据的新的能力。

Isentris 所具有的性能及节约成本优势的实例之一就是通过连接不同地理位置，且相距遥远实验室的广域网（WAN）改进业务。在广域网上，Isentris可以让科学家以比ISIS快15倍的速度完成诸如浏览化学记录的一般任务，以及以两到三倍的速度重新进行研究。这样的速度可以为许多公司的广域网配置多站点业务实践，从而大大降低了成本。

更多有关Isentris的信息，包括此次管理圆桌会议内容、白皮书及经典案例的信息可以登陆网站　www.mdl.com/executive　查询。

关于爱思唯尔MDL公司

爱思唯尔MDL公司（Elsevier MDL）提供信息学、数据库和工作流解决方案，可提高科学家决策的速度和水平，从而促进成功的科学研发。世界各地的研究人员依靠爱思唯尔MDL公司获取可靠的创新型发现信息学软件解决方案及服务。欲了解更多信息，请访问网站： www.mdl.com 。

MDL和Isentris是MDL信息系统有限公司（MDL Information Systems, Inc.）（爱思唯尔MDL公司）在美国的注册商标。保留所有权利。本文提及的其它所有商标均是其各自所有者的财产。

联系方式：爱思唯尔MDL公司（Elsevier MDL）

Jean Holt, 925-543-5400

高级总监，营销及通信部

j.holt@mdl.com

(BW)(CA-ELSEVIER-MDL)(RUK)(ENL)(REL.L)(REN.AS) New Approach for Integrating R&D Data and Workflows Gains Momentum in Pharmaceutical Industry

More Companies Migrating to MDL(R) Isentris(R) to Boost Productivity, Reduce Costs and Give Scientists More Control

SAN RAMON, Calif.--(BUSINESS WIRE)--Feb. 21, 2007--

More than 75 pharmaceutical, biotechnology and chemical companies have licensed the new, open-technology MDL(R) Isentris(R) system to address common R&D challenges, Elsevier MDL has announced. Leading research companies turning to the new-generation Isentris system include more than half of Elsevier MDL's top 30 customers.

The announcement came during a forum hosted by Elsevier MDL for research and IT executives from around the world to address strategies and new informatics technology for reducing R&D timelines, cutting costs and improving productivity.

"For more than a decade, almost every major pharmaceutical company has relied upon the current-standard, MDL(R) ISIS(R) technology in their labs," said President and CEO Lars Barfod, Elsevier MDL. "Many companies are now seeing the potential to realize significantly better results from their operations by migrating to Isentris. The recent Isentris 2.0 release far surpasses ISIS and competitive systems in terms of functionality, performance and lower cost of ownership."

With Isentris, organizations are giving scientists easier access to relevant data in the course of their normal workflows, and are facilitating coordination of the tools and capabilities needed to make decisions on that data. Isentris includes .NET controls for rapidly building customized, easy-to-use research environments with powerful scientific capabilities.

"The growing migration to Isentris reflects a new era, an 'Informatics 2.0' for scientists," said Dr. Trevor Heritage, Senior Vice President and Chief Scientific Officer, Elsevier MDL. "Researchers have control to create and access the specific views of data they need to answer questions and test hypotheses immediately -- without relying on IT support."

In a case study cited in the executive forum, a European pharmaceutical company that migrated to Isentris from ISIS praised the system's much improved integration and ease-of-use, and scientists' new ability to access biological assay data, chemistry and other experimental and calculated data as soon as it is created.

An example of Isentris performance and cost-saving advantages is improved operation over wide area networks (WAN) that connect geographically remote labs. On a WAN, Isentris lets scientists perform common tasks like browsing chemical records 15 times faster than ISIS, and retrieve searches two to three times faster. This speed makes WAN configurations practical for many organizations with multi-site operations, which in turn offer a path to significant cost savings.

More information about Isentris, including presentations from the executive roundtable session, white papers and case studies are available on www.mdl.com/executive .

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services. For more information, visit www.mdl.com .

MDL and Isentris are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

CONTACT: Elsevier MDL

Jean Holt, 925-543-5400

Senior Director, Marketing & Communications

j.holt@mdl.com